0001209191-22-014170.txt : 20220301
0001209191-22-014170.hdr.sgml : 20220301
20220301171812
ACCESSION NUMBER: 0001209191-22-014170
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220225
FILED AS OF DATE: 20220301
DATE AS OF CHANGE: 20220301
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Duraibabu Prathyusha
CENTRAL INDEX KEY: 0001779092
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 000-30171
FILM NUMBER: 22699723
MAIL ADDRESS:
STREET 1: C/O SANGAMO THERAPEUTICS, INC.
STREET 2: 501 CANAL BLVD.
CITY: RICHMOND
STATE: CA
ZIP: 94804
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: SANGAMO THERAPEUTICS, INC
CENTRAL INDEX KEY: 0001001233
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 680359556
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
BUSINESS PHONE: 5109706000
MAIL ADDRESS:
STREET 1: 7000 MARINA BLVD
CITY: BRISBANE
STATE: CA
ZIP: 94005
FORMER COMPANY:
FORMER CONFORMED NAME: SANGAMO BIOSCIENCES INC
DATE OF NAME CHANGE: 20000208
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-02-25
0
0001001233
SANGAMO THERAPEUTICS, INC
SGMO
0001779092
Duraibabu Prathyusha
C/O SANGAMO THERAPEUTICS, INC.
7000 MARINA BLVD.
BRISBANE
CA
94005
0
1
0
0
Vice President, Finance
Common Stock
2022-02-25
4
F
0
3474
5.90
D
46779
D
Common Stock
2022-02-25
4
A
0
41000
0.00
A
87779
D
Stock Option (Right to Buy)
5.90
2022-02-25
4
A
0
110700
0.00
A
2032-02-24
Common Stock
110700
110700
D
Represents shares underlying the portions of restricted stock unit ("RSU") grants that vested on February 25, 2022 which were surrendered by the Reporting Person to the Issuer for tax withholding using the Issuer's closing stock price on February 25, 2022 of $5.90/share, pursuant to the terms of the Issuer's Amended and Restated 2018 Equity Incentive Plan, as amended (the "2018 EIP").
Includes: (a) 3,609 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2020 RSU grant and 5,501 shares subject to such RSU grant that will vest in one final annual installment on February 25, 2023, (b) 2,999 shares resulting from the February 25, 2022 vesting of the Reporting Person's February 25, 2021 RSU grant and 9,167 shares subject to such RSU grant that will vest in two remaining annual installments of 4,583 shares and 4,584 shares on February 25, 2023 and 2024, respectively, (c) 2,000 shares subject to Reporting Person's March 25, 2020 RSU grant that will vest in two remaining annual installments of 1,000 shares on each of March 25, 2022 and 2023, (d) 1,917 shares subject to Reporting Person's April 25, 2019 RSU grant that will vest in one final annual installment on April 25, 2022 and (see footnote 3)
(e) 7,500 shares subject to Reporting Person's June 11, 2021 RSU grant that will vest in three annual installments of 2,500 shares on each of June 11, 2022, 2023 and 2024. The vesting of all such grants is subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Includes 426 shares acquired on October 29, 2021 under the Issuer's 2010 Employee Stock Purchase Plan.
Represents shares of common stock issuable upon settlement of an RSU grant that will vest as to one-quarter (1/4) of the shares on the first anniversary of the grant date, and the remainder of the shares will vest in 8 successive equal quarterly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
One-quarter (1/4) of the shares subject to the option will vest and become exercisable on the first anniversary of the grant date, and the remainder of the shares will vest and become exercisable in 24 successive equal monthly installments thereafter, subject to the Reporting Person's Continuous Service (as defined in the 2018 EIP) through each such date and subject to acceleration as provided in the 2018 EIP.
Prathyusha Duraibabu, by /s/ Ron A. Metzger, Attorney-in-Fact
2022-03-01